Cellular Therapy Innovations in Hematology

Cellular therapy uses living immune cells engineered or expanded to recognize and destroy malignant cells. Approved chimeric antigen receptor T cell products include tisagenlecleucel and brexucabtagene for B cell acute lymphoblastic leukemia, axicabtagene and lisocabtagene for diffuse large B cell lymphoma and follicular lymphoma, and idecabtagene plus ciltacabtagene against B cell maturation antigen for multiple myeloma.

Innovations under development include allogeneic off the shelf CAR T cell products from healthy donors with gene editing to remove T cell receptor and HLA expression and avoid graft versus host disease, CAR natural killer cells from cord blood or induced pluripotent stem cells with lower cytokine release syndrome, dual antigen CAR designs to prevent escape, and tumor infiltrating lymphocyte therapy approved for advanced melanoma.

Manufacturing remains complex with vein to vein time of three to five weeks, leukapheresis collection, viral vector or non viral gene transfer, ex vivo expansion, and quality release testing. Adverse effects include cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, prolonged cytopenias, hypogammaglobulinemia, and rare insertional mutagenesis. Ongoing research addresses solid tumor activity, persistence, and access barriers.